Sugi Predict

Sugi Predict / Compounds / SCHEMBL86359

SCHEMBL86359

SCHEMBL86359

CNC(=O)C(N)CCCC(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP8 Q6V1X1 6/20 0.47
▸ DPP9 Q86TI2 6/20 0.47
▸ DPP4 P27487 5/20 0.47
▸ KMT2A Q03164 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ DPP7 Q9UHL4 6/20 0.43
▸ SLC15A1 P46059 1/20 0.43
▸ BMP1 P13497 1/20 0.38
▸ GNAI3 P08754 1/20 0.38
▸ GNAO1 P09471 1/20 0.38
▸ GNAI1 P63096 1/20 0.38
▸ CHRM2 P08172 1/20 0.37
▸ CHRM4 P08173 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ RRM1 P23921 1/20 0.36
▸ NOS1 P29475 3/20 0.35
▸ NOS3 P29474 2/20 0.35
▸ NOS2 P35228 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325523 0.89 DPP4 (0.58) DPP8DPP9DPP4KMT2AALOX15
SCHEMBL85696 0.89 DPP4 (0.58) DPP8DPP9DPP4KMT2AALOX15
Hydrochloric Acid SCHEMBL7509758 0.88 DPP4 (0.56) DPP8DPP9DPP4KMT2AALOX15
Hydrochloric Acid SCHEMBL8466590 0.88 DPP4 (0.56) DPP8DPP9DPP4KMT2AALOX15
SCHEMBL8403553 0.87 DPP7 (0.48) DPP8DPP9DPP4DPP7SLC15A1
SCHEMBL8528049 0.81 DPP7 (0.51) DPP8DPP9DPP4DPP7SLC15A1
SCHEMBL15186165 0.81 DPP7 (0.63) DPP8DPP9DPP4DPP7SLC15A1
SCHEMBL14456838 0.81 DPP7 (0.51) DPP8DPP9DPP4DPP7SLC15A1
SCHEMBL4773570 0.81 DPP7 (0.51) DPP8DPP9DPP4DPP7SLC15A1
SCHEMBL3248464 0.81 DPP7 (0.63) DPP8DPP9DPP4DPP7SLC15A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656991-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2017-05-23 — — US disclosed
US-9650362-B2 Inhibitors PROBIODRUG AG (DE) 2017-05-16 — — US disclosed
US-9512115-B2 Inhibitors PROBIODRUG AG (DE) 2016-12-06 — — US disclosed
US-9512082-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2016-12-06 — — US disclosed
US-9462793-B2 Mouse carrying a knock-out mutation of the Qpct-gene PROBIODRUG AG (DE) 2016-10-11 — — US disclosed
US-9277737-B2 Mouse models carrying a knock-out mutation of the QPCTL-gene PROBIODRUG AG (DE) 2016-03-08 — — US disclosed
US-20160031869-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2016-02-04 — — US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 — — US disclosed
US-9173885-B2 Inhibitors PROBIODRUG AG (DE) 2015-11-03 — — US disclosed
US-9126987-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-09-08 — — US disclosed
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-09-11 — — US disclosed
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-04 — — US disclosed
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-08-28 — — US disclosed
US-20080200567-A1 IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS PROBIODRUG AG (DE) 2008-08-21 — — US disclosed
US-20080153892-A1 Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-06-26 — — US disclosed
US-7381537-B2 Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease PROBIODRUG AG (DE) 2008-06-03 — — US disclosed
US-7371871-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2008-05-13 — — US disclosed
US-7304086-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2007-12-04 — — US disclosed
US-20070191366-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES PROBIODRUG AG (DE) 2007-08-16 — — US disclosed
WO-2005039548-A2 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES PROBIODRUG AG (DE) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191366-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES GLS, QPCT, GLS2 DPP8 618/4885DPP9 424/4885DPP4 142/4885
US-20080153892-A1 Inhibitors of Glutaminyl Cyclase GLS2, GLS, GLUL DPP8 2740/4885DPP9 1148/4885DPP4 2049/4885
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL DPP8 2079/4885DPP9 1508/4885DPP4 1219/4885
US-20160031869-A1 NOVEL INHIBITORS GLS, GLUL, QPCT DPP8 2079/4885DPP9 841/4885DPP4 1319/4885
US-20080200567-A1 IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS QPCT, PCYT1A, PSEN2 DPP8 3733/4885DPP9 4061/4885DPP4 4178/4885
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL DPP8 1819/4885DPP9 1539/4885DPP4 1799/4885
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL DPP8 1372/4885DPP9 970/4885DPP4 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.